Veeva Systems beats Q2 estimates with EPS of $2.35

Veeva Systems reported fiscal second-quarter earnings of $2.35 a share, beating the $2.22 consensus estimate.

The beat extends Veeva's run of topping analyst forecasts as it expands its life-sciences software footprint. "We are honored to provide Vault CRM as the agentic commercial foundation for Biogen as it delivers medicines that transform patients' lives," Tom Schwenger, president and chief commercial officer at Veeva, said.

Metric	Actual	Consensus	Beat/Miss
EPS	$2.35	$2.22	+$0.13
Revenue	not disclosed	not disclosed	beat

Earnings compared with $1.99 a share in the year-ago quarter, a gain of 18 percent. Revenue also topped the Zacks Consensus Estimate, though the company did not disclose the dollar figure. Veeva, which trades on the New York Stock Exchange, serves more than 1,500 customers ranging from the largest pharmaceutical companies to emerging biotechs.

The results follow Veeva's announcement that Biogen committed to its Vault CRM platform globally. The deal, announced Aug. 25, makes Biogen the latest large biotech to adopt the company's commercial software, which includes the Agentic Call Report that generates commercial evidence using AI. Guy Hadari, senior vice president and global chief information officer at Biogen, said the move expands a strategic partnership with Veeva.

The Vault CRM Suite sits at the center of Veeva's push into agentic commercial, a model that uses AI to get the right medicines to more patients. The company, which operates as a Public Benefit Corporation, has built its business on replacing general-purpose tools from rivals such as Salesforce with software tailored to drugmakers' regulatory and compliance needs. Veeva's subscription model generates recurring revenue across its commercial and research-and-development clouds, giving it a base that has historically supported steady margin expansion.

The beat comes as Veeva pushes into agentic commercial tools that use AI to speed drug commercialization. The Biogen win adds a top-tier biotech to a customer base that already includes most major pharmaceutical companies. Investors will watch the earnings call for updated subscription revenue and guidance, as well as any changes to the company's full-year outlook.

The results show continued demand for Veeva's cloud software even as biotech funding remains uneven. The company's next event is the earnings call, where management is expected to detail subscription growth and the ramp of its Vault CRM suite.

This article is for informational purposes only and does not constitute investment advice.